Versartis' $25M Series C to Fund HGH Trial in Children
By Catherine Shaffer
Wednesday, January 16, 2013
Versartis Inc., of Redwood City, Calif., closed a $25 million Series C financing round through Aisling Capital, Index Ventures, New Leaf Venture Partners and Advent Venture Partners to support clinical trials of VRS-317 for growth hormone deficiency in children.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.